Engineered Milk‐Derived Extracellular Vesicles Integrate PCSK9 Silencing and Inflammation Modulation for Hyperlipidemia Therapy
Advanced Healthcare Materials · 11.11.2026
DOI: 10.1002/adhm.71963 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 11.11.2026. Verfasst von Qinyu Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China. Die Arbeit nennt 55 Literaturangaben. Gefördert von: "Open Competition to Select the Best Candidates" Key Technology Program for Nucleic Acid Drugs of NCTIB, National Natural Science Foundation of China, China Manned Space Program through its Scientific Research and Utilization System.
Abstract (Originalsprache)
Hyperlipidemia is a systemic metabolic disorder closely associated with chronic inflammation. Effective management requires integrated strategies that simultaneously lower lipid level and attenuate inflammation. Nucleic acid therapeutics, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) siRNA, represent a breakthrough in lipid‐lowering therapy. However, they either lack direct anti‐inflammatory effects (GalNAc‐siRNA) or are prone to triggering unintended inflammatory responses themselves such as lipid nanoparticles (LNPs). Milk‐derived extracellular vesicles (MDEs) emerge as naturally anti‐inflammatory nanocarriers that suppress key pro‐inflammatory cytokines by 30.0%–96.5% in vitro. However, MDEs predominantly undergo endocytic trafficking with substantial endosomal/lysosomal sequestration, which can limit productive cytosolic siRNA delivery. To address this, we developed engineered MDEs by incorporating 30.0% ( w/w ) probiotic‐derived glycolipids into their membranes to facilitate early endosomal escape. When loaded with PCSK9 siRNA, the engineered MDEs achieved a remarkable silencing efficiency of 90.2 ± 0.2%, significantly outperforming both unmodified MDEs and conventional LNPs. In hyperlipidemic mice, systemic administration of engineered MDEs improved serum lipid profiles, reduced lipid accumulation and systemic inflammation, and showed a favorable safety profile under the conditions examined. Collectively, this work provides a promising nucleic acid delivery platform based on engineered MDEs for enhanced hyperlipidemia therapy through simultaneous lipid‐lowering and anti‐inflammatory effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.
- State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- Department of Pharmacy, Medical College of Nanchang University, Nanchang, China.
- University of Chinese Academy of Sciences, Beijing, China.
- NMPA Key Laboratory For Quality Research and Evaluation of Pharmaceutical Excipients, National Institutes for Food and Drug Control, Beijing, China.
ORCID-Profile: Xiang Lu, Hongyu Liu, Miaorong Yu, Yong Gan
Förderung
- "Open Competition to Select the Best Candidates" Key Technology Program for Nucleic Acid Drugs of NCTIB
- National Natural Science Foundation of China
- China Manned Space Program through its Scientific Research and Utilization System
- National Key Research and Development Program of China
Zitieren
APA
Li, Q., Lu, X., Liu, Q., Liu, H., Ye, Y., Cui, Y., Liu, C., Aili, G., Liu, Y., Feng, H., Xu, A., Liang, L., Yu, M., Nie, D., & Gan, Y. (2026). Engineered Milk‐Derived Extracellular Vesicles Integrate PCSK9 Silencing and Inflammation Modulation for Hyperlipidemia Therapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71963
Vancouver
Li Q, Lu X, Liu Q, Liu H, Ye Y, Cui Y, et al. Engineered Milk‐Derived Extracellular Vesicles Integrate PCSK9 Silencing and Inflammation Modulation for Hyperlipidemia Therapy. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71963
BibTeX
@article{Li2026,
author = {Li, Qinyu and Lu, Xiang and Liu, Qing and Liu, Hongyu and Ye, Yangyuan and Cui, Ye and Liu, Chang and Aili, Gulixian and Liu, Yi and Feng, Hao and Xu, Anqi and Liang, Li and Yu, Miaorong and Nie, Di and Gan, Yong},
title = {Engineered Milk‐Derived Extracellular Vesicles Integrate PCSK9 Silencing and Inflammation Modulation for Hyperlipidemia Therapy},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71963}
}
EUVIMED